(Ceftibuten + xeruborbactam) is under clinical development by Qpex Biopharma and currently in Phase I for Pyelonephritis. According to GlobalData, Phase I drugs for Pyelonephritis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Ceftibuten + xeruborbactam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Ceftibuten + xeruborbactam) overview

The fixed dose combination of ceftibuten and xeruborbactam is under development for the treatment of complicated urinary tract infections including pyelonephritis. It is administered through oral route and acts by targeting penicillin binding protein (PBP) and beta-lactamase.

Qpex Biopharma overview

Qpex Biopharma, a subsidiary of Shionogi Inc, is a biopharmaceutical company that discovers and develops therapies for infectious diseases. The company’s pipeline products include ORAvance, OMNIvance and others. Its ORAvance, an oral treatment beta-lactamase inhibitor targeting extended-spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) infections; OMNIvance drug against infections caused due to acinetobacter, pseudomonas, and Enterobacteriaceae. The company operates in the US. Qpex Biopharma is headquartered in San Diego, California, the US.

For a complete picture of (Ceftibuten + xeruborbactam)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.